# AOD-9604 Clinical Dosing Guidelines

## Overview
AOD-9604 (Anti-Obesity Drug-9604) is a synthetic peptide derived from the C-terminal fragment of human growth hormone (amino acids 176-191). It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without affecting blood sugar or IGF-1 levels.

## Clinical Research Summary
Based on clinical trials and research studies, AOD-9604 has demonstrated efficacy in:
- Fat metabolism enhancement and weight loss
- Body composition improvement
- Metabolic function optimization
- Cartilage repair and joint health
- Injury recovery acceleration
- Anti-aging and regenerative effects

## Standard Concentrations

### Reconstitution Options
- **Option 1**: 1.0 mg/ml (dilute 5 mg in 5 ml bacteriostatic water)
- **Option 2**: 0.5 mg/ml (dilute 5 mg in 10 ml bacteriostatic water)
- **Option 3**: 1.67 mg/ml (dilute 5 mg in 3 ml bacteriostatic water)

### Storage
- **Lyophilized**: Store at -4°F, stable for 24+ months
- **Reconstituted**: Store at 39°F, use within 28 days
- **Stability**: Maintain cold chain for optimal potency

## Clinical Dosing Protocols

### Subcutaneous Administration (Primary Route)

#### Standard Weight Loss Protocol:
- **Concentration**: 0.5 mg/ml
- **Dose**: 0.3 mg per injection
- **Volume**: 0.6 ml
- **Frequency**: Once daily
- **Duration**: 8-12 weeks

#### Aggressive Fat Loss Protocol:
- **Concentration**: 1.0 mg/ml
- **Dose**: 0.5 mg per injection
- **Volume**: 0.5 ml
- **Frequency**: Once daily
- **Duration**: 6-8 weeks

#### Maintenance/Body Composition Protocol:
- **Concentration**: 0.5 mg/ml
- **Dose**: 0.25 mg per injection
- **Volume**: 0.5 ml
- **Frequency**: 5 days per week
- **Duration**: Long-term as needed

### Nasal Spray Administration (Alternative)

#### Intranasal Protocol:
- **Concentration**: 0.5 mg/ml
- **Dose**: 0.1-0.2 mg per spray
- **Volume**: 0.2-0.4 ml total daily
- **Frequency**: 2-3 sprays daily
- **Absorption**: Lower bioavailability than injection

## Dose Calculations by Body Weight

### Standard Dosing (1.36 mcg/lb)
| Body Weight | Dose (mg) | Volume (0.5 mg/ml) | Volume (1.0 mg/ml) |
|-------------|-----------|-------------------|-------------------|
| 110 lbs | 0.15 mg | 0.30 ml | 0.15 ml |
| 132 lbs | 0.18 mg | 0.36 ml | 0.18 ml |
| 154 lbs | 0.21 mg | 0.42 ml | 0.21 ml |
| 176 lbs | 0.24 mg | 0.48 ml | 0.24 ml |
| 198 lbs | 0.27 mg | 0.54 ml | 0.27 ml |
| 220 lbs | 0.30 mg | 0.60 ml | 0.30 ml |

### High-Dose Protocol (2.27 mcg/lb - Obese Patients)
| Body Weight | Dose (mg) | Volume (0.5 mg/ml) | Volume (1.0 mg/ml) |
|-------------|-----------|-------------------|-------------------|
| 110 lbs | 0.25 mg | 0.50 ml | 0.25 ml |
| 154 lbs | 0.35 mg | 0.70 ml | 0.35 ml |
| 198 lbs | 0.45 mg | 0.90 ml | 0.45 ml |
| 220 lbs | 0.50 mg | 1.00 ml | 0.50 ml |

### Conservative Dosing (0.68 mcg/lb - Initial Treatment)
| Body Weight | Dose (mg) | Volume (0.5 mg/ml) | Volume (1.67 mg/ml) |
|-------------|-----------|-------------------|-------------------|
| 110 lbs | 0.075 mg | 0.15 ml | 0.045 ml |
| 154 lbs | 0.105 mg | 0.21 ml | 0.063 ml |
| 198 lbs | 0.135 mg | 0.27 ml | 0.081 ml |
| 220 lbs | 0.15 mg | 0.30 ml | 0.090 ml |

## Clinical Applications

### Obesity Treatment:
- **Concentration**: 1.0 mg/ml
- **Dose**: 0.3-0.5 mg daily
- **Duration**: 12-24 weeks
- **Monitoring**: Weight, body composition, metabolic markers

### Body Composition Optimization:
- **Concentration**: 0.5 mg/ml
- **Dose**: 0.25-0.3 mg daily
- **Duration**: 8-16 weeks
- **Monitoring**: DEXA scan, waist circumference

### Metabolic Enhancement:
- **Concentration**: 0.5 mg/ml
- **Dose**: 0.2-0.3 mg daily
- **Duration**: 12 weeks minimum
- **Monitoring**: Lipid profile, insulin sensitivity

### Joint/Cartilage Support:
- **Concentration**: 0.5 mg/ml
- **Dose**: 0.25 mg daily
- **Duration**: 16-24 weeks
- **Monitoring**: Joint function, pain scores

## Administration Guidelines

### Injection Technique:
1. Use 27-31 gauge, 0.5 inch needle
2. Clean injection site thoroughly
3. Inject into subcutaneous tissue of abdomen or thigh
4. Rotate injection sites to prevent lipodystrophy
5. Inject slowly and steadily

### Timing Considerations:
- **Optimal**: Empty stomach (fasting state)
- **Morning**: Preferred administration time
- **Pre-Exercise**: 30-60 minutes before workout for enhanced fat oxidation
- **Avoid**: Within 2 hours of meals

### Cycling Protocols:
- **Standard Cycle**: 8-12 weeks on, 2-4 weeks off
- **Continuous Use**: Monitor for effectiveness plateau
- **Break Periods**: Allow metabolic reset
- **Long-term**: Periodic dose holidays recommended

## Safety Parameters

### Baseline Testing:
- Comprehensive metabolic panel
- Lipid profile
- Thyroid function tests
- Body composition analysis
- Cardiovascular assessment

### Monitoring During Treatment:
- Monthly weight and body composition
- Quarterly lipid profile
- Blood glucose monitoring
- Injection site assessment
- Adverse event monitoring

### Contraindications:
- Known hypersensitivity to AOD-9604
- Active malignancy (relative contraindication)
- Severe cardiovascular disease
- Pregnancy/lactation (insufficient data)

### Adverse Effects:
- Generally well-tolerated in clinical trials
- Injection site reactions (mild, transient)
- Rare: headache, nausea, dizziness
- No significant impact on blood glucose or growth
- No serious adverse events reported at recommended doses

## Special Considerations

### Fat Loss Mechanisms:
- Stimulates lipolysis via beta-3 adrenergic receptors
- Inhibits lipogenesis in adipocytes
- Does not affect glucose metabolism or insulin sensitivity
- Preserves lean muscle mass during weight loss

### Exercise Synergy:
- Enhanced fat oxidation during exercise
- Improved body composition when combined with resistance training
- Consider timing with workout schedules
- May improve exercise recovery

### Diet Considerations:
- Most effective in caloric deficit
- Enhanced effects with low-carbohydrate diets
- Fasting state administration preferred
- Monitor for adequate protein intake

### Age-Related Factors:
- **Adults**: Standard dosing generally appropriate
- **Elderly**: May require dose adjustment for metabolism
- **Younger Adults**: Often respond well to lower doses

## Clinical Endpoints

### Treatment Success Indicators:
- Body weight reduction ≥5% from baseline
- Decreased body fat percentage
- Improved waist-to-hip ratio
- Enhanced lipid profile
- Maintained or increased lean muscle mass

### Metabolic Markers:
- **Primary**: Body fat percentage reduction
- **Secondary**: Improved lipid ratios
- **Tertiary**: Enhanced metabolic rate
- **Additional**: Better insulin sensitivity

### Body Composition Goals:
- **Fat Loss**: 1-2 lbs per week sustainable loss
- **Muscle Preservation**: Maintain lean mass during deficit
- **Measurement**: DEXA scan or bioimpedance analysis
- **Progress**: Monthly assessments recommended

### Duration Guidelines:
- **Initial Effects**: 2-4 weeks for early fat loss
- **Significant Changes**: 6-8 weeks for measurable body composition changes
- **Optimal Results**: 12-16 weeks for maximum benefit
- **Maintenance**: Reduced dosing for weight maintenance

### Combination Therapy:
- Often combined with lifestyle interventions
- May enhance effects of caloric restriction
- Consider with exercise programs
- Coordinate with comprehensive weight management